Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
Head-to-head study demonstrates Focalin® XR offers faster and better symptom control than Concerta® in early part of ADHD patients day
July 22nd, 2008
A head-to-head study, published in the June Journal of Child and Adolescent Psychopharmacology, confirms that Focalin® XR (dexmethylphenidate HCl) extended-release capsules offer greater improvements in managing symptoms of Attention Deficit/Hyperactivity Disorder compared with Concerta® (d,l- methylphenidate HCl) extended-release tablets at two hours post-dose, the primary study endpoint. Focalin XR 20 mg and 30 mg2 also demonstrated better symptom control versus Concerta 36 mg and 54 mg respectively, from 30 minutes to 6 hours. Symptom control was demonstrated as early as 30 minutes post-dose with Focalin XR 20 mg and 30 mg versus placebo. Neither dose of Concerta...
Source: Cancer Weekly (2008-07-22)
|
